Related Experiment Video

Updated: Feb 5, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

1.3K

The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus

H G Ternavasio-de la Vega1, F Castaño-Romero1, S Ragozzino1

  • 1Department of Internal Medicine,University Hospital of Salamanca,Salamanca,Spain.

Epidemiology and Infection
|September 4, 2018
PubMed

Insights

The updated Charlson Comorbidity Index (uCCI) better predicts 30-day mortality in Staphylococcus aureus bacteraemia (SAB) patients than the classical CCI. A uCCI score of 4 or higher independently indicated higher mortality risk in SAB patients.

Area of Science:

  • Medical research
  • Clinical epidemiology
  • Infectious diseases

Background:

  • Staphylococcus aureus bacteraemia (SAB) poses a significant mortality risk.
  • Accurate prediction of mortality is crucial for patient management.
  • The classical Charlson Comorbidity Index (CCI) is widely used but may require updates.

Purpose of the Study:

  • To compare the predictive performance of the updated CCI (uCCI) and the classical CCI (cCCI) for 30-day mortality in SAB patients.
  • To evaluate the utility of uCCI and cCCI in identifying high-risk SAB individuals.

Main Methods:

  • Prospective cohort study of SAB patients aged 14 years or older.
  • Comorbidity assessment using both cCCI and uCCI.
  • Multivariate logistic regression models incorporating CCI scores and other relevant variables to predict 30-day mortality.

Main Results:

  • A total of 257 SAB episodes were analyzed; 25% of patients died within 30 days.
  • The cCCI score did not show a significant association with mortality.
  • An updated CCI score of 4 or higher was an independent predictor of 30-day mortality (OR, 1.98; 95% CI, 1.05-3.74).

Conclusions:

  • The updated Charlson Comorbidity Index (uCCI) demonstrates superior performance in predicting 30-day mortality among SAB patients compared to the classical CCI.
  • The uCCI is a more refined and parsimonious prognostic tool, aiding in the identification of SAB patients with a worse prognosis.

Keywords:
Bacteraemiacomorbiditymortalitystaphylococcus aureus

More Related Videos

Genotyping of Staphylococcus aureus by Ribosomal Spacer PCR RS-PCR08:51

Genotyping of Staphylococcus aureus by Ribosomal Spacer PCR RS-PCR

Published on: November 4, 2016

10.2K
Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes12:27

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes

Published on: January 3, 2020

6.8K

Related Concept Videos

Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
239
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314